Topic summary

Revisiting: Why a compound being unapproved is not the same as being illegal to possess

Sourcing › Regulatory FDA EMA compounding research use only personal import Closed

This is a generated summary. It shows the 9 most-liked posts from a topic of 83, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

ca.haddadTL24 May 2025#1

On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion.

I would like to know what people here actually do about compound being unapproved, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.

Mine is below, with the reasoning, including the parts I am not confident about.

44 likes 15mo

m.dalgaardTL3Regular14 May 2025#5

ca.haddad, post #1: On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. I would like to know what people here actually do about compound being unapproved, as distinct from what is usually recommended. Those have diverged in every other subject I have… Go to post

Careful with the language on compound being unapproved. "Not detected" and "not present" are different findings and the first is a statement about the method.

32 likes in reply to #1 14mo

f.novakTL26 Jun 2025#19

Post #15 and I disagree about the size of the effect, not about the direction.

Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.

Not a strong opinion, just a consistent one.

26 likes 14mo

logbook_erinTL3Regular9 Jun 2025#21

The reason compound being unapproved keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.

33 likes 14mo

e.mikkelsenTL2Member27 Jun 2025#35

A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.

31 likes 13mo

k.batistaTL24 Jul 2025#41

Compound being unapproved: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

30 likes 13mo

IMainwaringTL3Regular14 Jul 2025#50

I read post #48 twice before replying, because I had assumed the opposite.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

That is the version I would defend. It is not the version I started with.

31 likes 12mo

m.adebayoTL220 Jul 2025#55

g.tanaka, post #9: Narrowing post #6, because the general version has more than one answer. Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold. Adding a source would improve this… Go to post

Everything in post #51 holds. The case it does not cover is the one I have.

I would call the community position on compound being unapproved likely rather than established, and I would be comfortable defending that hedge.

28 likes in reply to #9 12mo

two_year_lineTL3Regular31 Jul 2025#65

Compound being unapproved has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.

27 likes 12mo

Read the full topic (83 posts)

This topic was referenced in

Reading a regulatory notice rather than an article about itSourcing › Regulatory · 2 replies

This topic was closed 120 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
What a regulator's shortage notice actually authorises — what changed since Sourcing › Regulatory research use only EMA FDA compounding Solved The question in the title: What a regulator's shortage notice actually authorises — what changed since I will give what I have already checked below so nobody repeats it. Asking what a regulator's document…	+22	26	53k	7mo
Research-use-only labelling: what it means and what it does not — the long version Sourcing › Regulatory EMA research use only compounding Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not — the long version Everything below is what sits behind that. A labelling question, and I would like…	+150	158	55k	14mo
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…	+72	77	1.5k	1d
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…	+100	110	37k	5mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…		2	5k	11mo

Related topics — sharing the tags FDA, EMA, compounding

Topic	Participants	Replies	Views	Activity
Why catalogue breadth is not evidence of anything — what changed since Compounds › Other compounds custom synthesis mislabelling needs a source research use only Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since What changes if the standard account of catalogue breadth is wrong? I ask…	+62	66	26k	10mo
How to research a compound with no human data without deceiving yourself Compounds › Other compounds needs a source mislabelling custom synthesis research use only Solved Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Question about what the published evidence for this compound actually…	+107	119	11k	12mo
Pen wastage and its effect on real cost — the long version Access › Pricing formulary data table cost per milligram compounding Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. A narrow question about Pen wastage, deliberately narrow,…		2	34k	13mo
A payment that went through twice: how it was resolved Sourcing › Payments payments research use only documentation quality Solved Closed A payment that went through twice: how it was resolved Writing it up because I had to work it out twice and would rather nobody else did. A payments question, with the mechanics separated from the money. What…	+20	24	55k	3mo
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about the compound itself rather than about a trial of it. I…	+77	82	12k	11mo